全文获取类型
收费全文 | 421360篇 |
免费 | 32031篇 |
国内免费 | 9021篇 |
专业分类
耳鼻咽喉 | 4425篇 |
儿科学 | 11077篇 |
妇产科学 | 7688篇 |
基础医学 | 31065篇 |
口腔科学 | 10718篇 |
临床医学 | 53214篇 |
内科学 | 50441篇 |
皮肤病学 | 5481篇 |
神经病学 | 22582篇 |
特种医学 | 8992篇 |
外国民族医学 | 40篇 |
外科学 | 44400篇 |
综合类 | 64553篇 |
现状与发展 | 21篇 |
一般理论 | 53篇 |
预防医学 | 48030篇 |
眼科学 | 6215篇 |
药学 | 40124篇 |
884篇 | |
中国医学 | 35624篇 |
肿瘤学 | 16785篇 |
出版年
2023年 | 7115篇 |
2022年 | 12097篇 |
2021年 | 17862篇 |
2020年 | 17772篇 |
2019年 | 21847篇 |
2018年 | 19324篇 |
2017年 | 16606篇 |
2016年 | 14099篇 |
2015年 | 13075篇 |
2014年 | 26605篇 |
2013年 | 28224篇 |
2012年 | 23878篇 |
2011年 | 25436篇 |
2010年 | 20367篇 |
2009年 | 18482篇 |
2008年 | 17970篇 |
2007年 | 18247篇 |
2006年 | 15975篇 |
2005年 | 13623篇 |
2004年 | 11215篇 |
2003年 | 9717篇 |
2002年 | 7581篇 |
2001年 | 6689篇 |
2000年 | 5498篇 |
1999年 | 4678篇 |
1998年 | 3861篇 |
1997年 | 3624篇 |
1996年 | 3127篇 |
1995年 | 2902篇 |
1994年 | 2819篇 |
1993年 | 2218篇 |
1992年 | 2244篇 |
1991年 | 1937篇 |
1990年 | 1703篇 |
1989年 | 1534篇 |
1988年 | 1450篇 |
1987年 | 1251篇 |
1985年 | 3897篇 |
1984年 | 4881篇 |
1983年 | 3399篇 |
1982年 | 3856篇 |
1981年 | 3594篇 |
1980年 | 3201篇 |
1979年 | 2928篇 |
1978年 | 2549篇 |
1977年 | 1921篇 |
1976年 | 2168篇 |
1975年 | 1649篇 |
1974年 | 1436篇 |
1973年 | 1283篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
102.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献
103.
104.
《Vaccine》2022,40(11):1594-1605
In addition to providing pathogen-specific immunity, vaccines can also confer nonspecific effects (NSEs) on mortality and morbidity unrelated to the targeted disease. Immunisation with live vaccines, such as the BCG vaccine, has generally been associated with significantly reduced all-cause infant mortality. In contrast, some inactivated vaccines, such as the diphtheria, tetanus, whole-cell pertussis (DTPw) vaccine, have been controversially associated with increased all-cause mortality especially in female infants in high-mortality settings. The NSEs associated with BCG have been attributed, in part, to the induction of trained immunity, an epigenetic and metabolic reprograming of innate immune cells, increasing their responsiveness to subsequent microbial encounters. Whether non-live vaccines such as DTPw induce trained immunity is currently poorly understood. Here, we report that immunisation of mice with DTPw induced a unique program of trained immunity in comparison to BCG immunised mice. Altered monocyte and DC cytokine responses were evident in DTPw immunised mice even months after vaccination. Furthermore, splenic cDCs from DTPw immunised mice had altered chromatin accessibility at loci involved in immunity and metabolism, suggesting that these changes were epigenetically mediated. Interestingly, changing the order in which the BCG and DTPw vaccines were co-administered to mice altered subsequent trained immune responses. Given these differences in trained immunity, we also assessed whether administration of these vaccines altered susceptibility to sepsis in two different mouse models. Immunisation with either BCG or a DTPw-containing vaccine prior to the induction of sepsis did not significantly alter survival. Further studies are now needed to more fully investigate the potential consequences of DTPw induced trained immunity in different contexts and to assess whether other non-live vaccines also induce similar changes. 相似文献
105.
106.
107.
108.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol 下载免费PDF全文
109.
目的观察膀胱肿瘤切除术后患者尿路感染发生情况与病原学特征,分析诱发尿路感染的危险因素,并提出合理且具备针对性的冲洗对策,为未来膀胱肿瘤切除术后尿路感染的预防提供合理参考。方法回顾性分析连云港市第一人民医院2016年1月-2019年1月接受经尿道膀胱肿瘤切除术治疗的451例膀胱肿瘤患者的临床资料,收集患者病例资料,全部患者术后均定期取尿液标本进行细菌培养,参照相关标准判定患者尿路感染情况,记录患者一般情况,包括一般人口学资料(性别、年龄、体质量、受教育程度等),同时记录患者糖尿病的疾病合并情况,将术后尿路感染可能的危险因素纳入初步分析,Logistic多因素回归分析膀胱肿瘤切除术后发生尿路感染的危险因素。结果451例膀胱肿瘤切除术患者术后第3天尿液中细菌培养阳性例数为80例,阳性率为17.74%,在使用抗菌药物后,患者尿液中细菌培养阳性率逐渐降低,各时点尿液细菌阳性培养率比较,差异有统计学意义(P<0.05);经多因素Logistic回归分析检验证实,高龄、血糖水平控制不佳、术前留置导尿管、多发肿瘤是膀胱肿瘤切除术后尿路感染的危险因素(OR>1,P<0.05);80例术后尿液细菌培养阳性患者共分离出87株菌株,其中革兰阴性菌66株占75.86%,革兰阳性球菌21株占24.14%。结论膀胱肿瘤切除术后患者有较高的尿路感染风险,革兰阴性菌是主要的感染病原菌,年龄、基础疾病、肿瘤位点、术前导尿管留置等是影响因素,这类患者应引起临床高度重视。 相似文献
110.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献